News Article
Sarclisa (isatuximab-irfc) Approved as a Subcutaneous Injection for Multiple Myeloma by the FDAOn July 9, 2026, the U.S. FDA "approved isatuximab-irfc (Sarclisa Escena, Sanofi-Aventis U.S. LLC) for subcutaneous injection for multiple myeloma indications." According to an FDA press release, those…
Videos
Bispecifics, CELMoDs and "In Vivo" CAR T: Research Breakthroughs From Major Medical ConferencesCAR T Made Inside the Body?Multiple myeloma research is moving rapidly, but which developments are most likely to affect you and your loved one? Dr. Joseph Mikhael reviews…
Videos
High-Risk Smoldering Myeloma: Is It Time for Treatment? | Myeloma in a MinuteIs it time to treat high-risk smoldering multiple myeloma (HRSMM) instead of continuing to "watch and wait"? In this quick explainer video, Dr. Joseph Mikhael…
News Article
CHMP-EMA issues positive opinion on Tecvayli (teclistamab) for relapsed/refractory myeloma, with new recommendations on marketing authorization On Thursday, June 25, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) “adopted a…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the June 2026 edition.The IMF team of medical editors has provided overviews of key studies. Yet, we…
Videos
Hosted by Heather Cooper Ortner (IMF President & CEO) with panelists Dr. S. Vincent Rajkumar (Mayo Clinic / IMWG Chair), Dr. Sagar Lonial (Emory University / Winship Cancer Institute), and Dr. Nikhil Munshi (Dana-Farber / Harvard Medical School). The webinar covered key data readouts from ASCO…
Page
The Benefits of Exercising With Multiple MyelomaStudies have shown that exercising with myeloma can provide several health benefits, such as:Bone density and strength…
IMF Person
Roman Cuilla Martinez is a multi-disciplinary creative director in Los Angeles, California. With a background in commercial production and entertainment, Roman has collaborated with world-class agencies on projects for Vogue, Target, and American Express. A documentary filmmaker, he brings a human-…
News Article
Data from Phase 3 MonumenTAL-3 study show "impressive results on talquetamab plus daratumumab as a potential new bispecific combination for patients with relapsed or refractory multiple myeloma," says Dr. Peter M. Voorhees, who presented the findings at the EHA 2026 Congress. On Saturday, June…
News Article
International Myeloma Foundation’s Black Swan Research Initiative Presents Data and Results of Phase 2 ASCENT Cure Trial at EHA 2026 CongressQuadruplet Dara-KRd combination demonstrates high rates of response in high-risk smoldering myeloma patients similar to that observed in NDMM; MRD negativity…
The Lancet Publishes Interim Analysis Data for the SUCCESSOR-2 Trial, Presented at 2026 ASCO and EHA
News Article
The medical journal The Lancet has published interim analysis data from the SUCCESSOR-2 trial, which were presented at the 2026 American Society of Clinical Oncology (ASCO) and the 2026 European…
IMF Person
Christa Kosobucki is a Meetings and Events Planner with the International Myeloma Foundation. Born in Hawaii, raised in Canada, and having lived in the Middle East, she developed an early passion for international relations, later earning her MA from McGill University. Her global experience…
Videos
CAR T-Cell Therapy: Who Is a Candidate? | Myeloma in a MinuteCould you be a candidate for CAR T-cell therapy to treat multiple myeloma? In this quick expert explainer video, Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO discusses who may be…
Page
The Role of Nutrition in Multiple MyelomaWe understand the need for a positive mindset and action plan when someone has multiple myeloma. Diet and proper nutrition contribute to these in several ways.Your body craves nutrient-rich foods during treatment. Good nutrition during myeloma treatment can…
Page
Exercise and Physical ActivityProper wellness for people living with myeloma and caregivers is partly comprised of movement. Our comprehensive myeloma wellness resources include:Mobility and safety tips…
News Article
International Myeloma Foundation (IMF) and International Myeloma Working Group (IMWG) to Honor 2026 Kyle and Durie Achievement Awardees, Dr. Hermann Einsele and Dr. Noopur RajeAwarding ceremonies to be held today, June 9, 2026, at the 17th Annual IMWG Summit in…
Page
Double Your Impact. Help More People Affected by Myeloma.Many employers offer matching gift programs that can double—or even triple—the value of your donation. By submitting a matching gift request, you can help fund more research, provide more free educational resources, and support more families…
News Article
Sarclisa (isatuximab) SC — the first anticancer therapy approved by the European Union (EU) to be administered through an on-body injector (OBI) — "can provide the flexibility of administration at patients’ homes and in the outpatient setting." On Monday, June 8, Sanofi announced in a…
Page
/* USMN Logo */
.usmn-logo {
width: 100%;
max-width: 530px;
margin: 35px auto 38px;
text-align: center;
}
.usmn-logo img {
display: block;
width: 100%;
max-width: 100%;
height: auto !important;
margin: 0 auto;
}
/* USMN Network Map */
.usmn-hero {
width: 100…
Videos
What Are Trispecific Antibodies in Multiple Myeloma? | Myeloma in a Minute What are trispecific antibodies, and how could they affect multiple myeloma treatment? In this quick explainer video, Dr. Joseph Mikhael breaks down the difference between bispecific antibodies and emerging trispecific…
IMF Person
Jennifer Schlesinger has spent more than 20 years working in the public sector and with nonprofit health organizations. She has overseen professional training and outreach programs, community and health education, healthcare advocacy, and technical assistance and support to healthcare systems…
Videos
How Long Will I Live With Multiple Myeloma? | Myeloma Expert Answers in a Minute or Less"How long will I live with myeloma?" It's one of the first questions patients and families ask after diagnosis. In this video, myeloma expert Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO, explains…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the May 2026 edition.The IMF team of medical editors has provided overviews of key studies. Yet, we encourage…
Videos
What Happens After CAR T-Cell Therapy? Myeloma Experts Answer Common QuestionsWhat happens to your immune system after CAR T-cell therapy? How long should patients stay on lenalidomide maintenance? And how do people keep track of all their myeloma labs, medications, and treatment changes?In this…
Videos
Can You Live a Normal Life With Multiple Myeloma? Real Answers From Myeloma Experts What happens after a multiple myeloma diagnosis? What questions should you ask your doctor? And can people actually live normal lives with myeloma today?In this video, Dr. Joseph Mikhael and Beth Faiman answer…
News Article
We Are #MoreThanMyeloma on Capitol HillBy Danielle Doheny, IMF Director, Public Policy & AdvocacyDuring Myeloma Action Month (MAM) in March 2026, the International Myeloma Foundation (IMF) brought patients, care partners, and advocates to Capitol Hill, ensuring that the voices…
Videos
What “Cure” Really Means in Multiple Myeloma | MRD & Long-Term Remission ExplainedCan multiple myeloma actually be cured? For the first time, myeloma researchers and clinicians are formally discussing and defining what “cure” could mean for patients living…
News Article
2026 MAM Global Campaign Demonstrates the Spirit of #MoreThanMyelomaOver 60 million in 96 countries celebrate resilience, strengthen connections, and inspire hopeBy Peter Anton, IMF Vice President, MarketingAs the 2026 Myeloma Action Month (MAM) annual global awareness campaign…
Page
Remission vs. Cure: Understanding the Difference in Multiple MyelomaRemission is when the signs and symptoms of multiple myeloma, including the key tests that measure the disease, are reduced or have disappeared. This can occur in different levels, including partial, very good partial response (…
Page
How Long Can You Live With Multiple Myeloma?As with any chronic disease, life expectancy statistics can vary among individuals, depending on the stage of detection and risk factors. Recent published studies have shown the average multiple…
IMF Person
Randy Marsh is an experienced nonprofit operations executive with over 20 years’ experience leading teams managing HR, Finance, Accounting, IT, Contract, Legal, and Facilities in nonprofit, government, and for-profit organizations. Randy has spent over a decade serving on nonprofit boards,…
News Article
The DVRd RegimenThis standard-of-care quadruplet combination is now FDA-approved for the majority of patients with newly diagnosed multiple myeloma On January 27, 2026, the U.S. Food and Drug Administration (FDA) approved the use of the quadruplet (4-drug) combination of Darzalex Faspro® (…
Page
We take pride in providing impactful and transformative community support programs, events, seminars, and conferences. As part of our commitment to transparency, integrity, and accountability, we provide an anonymous reporting option for anyone who wish to share feedback or raise concerns related…
News Article
Phase 3 MagnetisMM-5 Trial Shows Statistically Significant and Clinically Meaningful Improvement in Primary Endpoint of Progression-Free Survival Using Elranatamab vs Daratumumab Plus Pomalidomide and Dexamethasone (DPd), as Evaluated by Blinded Independent Central Review (BICR) On Wednesday,…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the April 2026 edition.The IMF team of medical editors has provided overviews of key studies. Yet, we…
News Article
Living with Blood Cancer, Riding for a Cure: The Cyclists Taking on Iceland What does it take to cycle across one of the world’s most rugged and awe-inspiring landscapes while living with cancer? This summer, a remarkable group of riders will answer that question during the International…
Videos
Description:This module equips oncology nurses with practical strategies to safely initiate, monitor, and manage BCMA‑targeted bispecific antibodies for multiple myeloma in community practice settings.Learning Objectives:…
Videos
Description:Learn practical strategies to recognize, monitor, and manage cytokine release syndrome (CRS), neurotoxicity (ICANS), and infection risk associated with bispecific antibody therapy in multiple myeloma, with an emphasis on patient safety and care coordination.…
Videos
CRS Explained: What Myeloma Patients Need to Know (CAR-T Side Effects in 60 Seconds)CRS, or cytokine release syndrome, is a common side effect of treatments like CAR T-cell therapy and bispecific antibodies in multiple myeloma. But what does it actually mean, and should patients be concerned?In…
Videos
Description:Learn about transitions of care in multiple myeloma, emphasizing the importance of coordinated communication.Learning Objectives:Identify key transition points requiring enhanced coordination…
Videos
DOWNLOAD SLIDES
Page
CAR T-Cell Therapy for Myeloma: Overview and BenefitsChimeric antigen receptor (CAR) T-Cell therapy is a cutting-edge, personalized treatment for myeloma that uses your own T-cells to target cancer. The process involves collecting and modifying your T-cells, followed by infusion and close…